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Background:We have combined functional gene polymorphisms with clinical factors to improve prediction and
understanding of sporadic breast cancer risk, particularly within a high incidence Caucasian population.
Methods: A polyfactorial risk model (PFRM) was built from both clinical data and functional single nucleotide
polymorphism (SNP) gene candidates using multivariate logistic regression analysis on data from 5022 US
Caucasian females (1671 breast cancer cases, 3351 controls), validated in an independent set of 1193 women
(400 cases, 793 controls), and reassessed in a unique high incidence breast cancer population (165 cases, 173
controls) from Marin County, CA.
Results: The optimized PFRM consisted of 22 SNPs (19 genes, 6 regulating steroid metabolism) and 5 clinical risk
factors, and its 5-year and lifetime risk prediction performance proved signiﬁcantly superior (~2-fold) over the
Gail model (Breast Cancer Risk Assessment Tool, BCRAT), whether assessed by odds (OR) or positive likelihood
(PLR) ratios over increasing model risk levels. Improved performance of the PFRM in high risk Marin women
was due in part to genotype enrichment by a CYP11B2 (-344T/C) variant.
Conclusions and general signiﬁcance: Since the optimized PFRM consistently outperformed BCRAT in all Caucasian
study populations, it represents an improved personalized risk assessment tool. The ﬁnding of higher Marin
County risk linked to a CYP11B2 aldosterone synthase SNP associated with essential hypertension offers a new
genetic clue to sporadic breast cancer predisposition.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Breast cancer continues to be a common cancer in USwomenwith a
lifetime risk of ~12% (1 in 8), with an ever-increasing and overall (age
adjusted) incidence of ~127 per 100,000 for non-Hispanic Caucasian
women [1]. The annual breast cancer-speciﬁc mortality rate, decliningon Aging, 8001 Redwood Blvd.,
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ies, Oklahoma City, OK, USA.
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ad, CA, USA.
er, Pryor, OK, USA.
. This is an open access article underslightly due to early detection and treatment advances, is still ~25 per
100,000 overall, with a 5-year breast cancer-speciﬁc death rate of 14%
for non-Hispanic Caucasian women, and remains the leading cause of
cancer deaths for all women age 40–55. A key to improving breast can-
cer survival is early detection [2], achieved in part by identifying new
risk factors and better models for estimating individual breast cancer
risk [3,4]. Improvements in individualized risk estimation would allow
more accurate identiﬁcation of those women most likely to beneﬁt
from regular screening with more sensitive methods or from more
aggressive prevention strategies [5,6].
The National Cancer Institute Breast Cancer Risk Assessment Tool
(BCRAT), or Gailmodel, and its updated versions are themost common-
ly used tools for breast cancer risk estimation [7,8], with attention turn-
ing to methods that might improve upon its predictive accuracy. Thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mate the number of cancers likely to emerge in a population of women
seeking regular mammography screening [9–11], but, for individual pa-
tient counseling, it lacks the desired discriminatory accuracy [12,13]. In-
cremental improvements in the BCRAT have been achieved by the
addition of additional clinical risk factors including ﬁne needle aspirate
cytology [14] as well as mammographic density and weight [15]; how-
ever, such modiﬁcations have not been adopted for widespread use.
Common variants in candidate genes with probable physiological roles
in pathways involved in breast carcinogenesis have long been studied
for association with breast cancer [16,17]. Independently, genome
wide association studies (GWASs) have identiﬁed a core group of
7–10 single nucleotide polymorphisms (SNPs) associated with breast
cancer, most of which do not have any known functional consequence
or obvious role in the disease process [18–22]. For both candidate and
GWAS identiﬁed SNPs the risks conferred by any one gene variant are
small tomodest (OR=1.2–1.5) and cannot be used to effectively deter-
mine risk. Investigators have suggested that breast cancer risk for thema-
jority of women (including familial associated but BRCA1/2-negative
cancers) is likely to bepolygenic [23–26], and several studies have utilized
estimates of relative risks and allele frequencies for the GWAS SNPs to
determine if multiplicative risk estimates for the SNPs alone or SNPsmul-
tiplied by BCRAT risks improve risk estimation [27–31]. These studies
have reported minimal improvements in risk prediction.
In order to develop a newpolyfactorial breast cancer risk assessment
model (PFRM), we have taken a candidate gene approach [26,32],
similar to that used for the successful development of multigene assays
routinely used to predict the likelihood of developing a distant recur-
rence in a newly diagnosed breast cancer patient [34], and built an
age-speciﬁc model that integrates these genetic factors with known
clinical breast cancer risk factors [33]. Common functional SNPs in can-
didate genes known or likely to inﬂuence breast cancer development
were ﬁrst identiﬁed from the published literature and genomic data-
bases. Genotyping and clinical risk factor data were then combined for
each individual in large model building and validation case–control
datasets consisting of participants enrolled from multiple geographic
regions within the US. A multi-step statistical protocol employing
multivariate logistic regression was used to build the ﬁnal model, and
the performance of this optimized PFRM was evaluated relative to the
widely used BCRAT, and then reassessed using another independent
dataset of DNA samples and clinical risk data from case–control partici-
pants enrolled from a very high incidence breast cancer population in
Marin County, CA [35,36].
2. Materials and methods
2.1. Model building and validation study populations
As described previously, the study population consisted ofwomen in
a case–control study conducted from 1996 through 2006, in Oklahoma
City (OK), Seattle (WA), San Diego (CA), Kansas City (KS and MO),
Orlando (FL), and Charleston (SC) [26,32]. At each site, most women
approached were enrolled in the study; cases self-reported a diagnosis
of breast cancer at any time, and controls reported no diagnosis of any
cancer. Participants at mammography clinics were either newly
diagnosed (or follow-up) cases, or were cancer-free controls based on
history and screening. Caseswere also enrolled in surgery and oncology
clinics with controls obtained in general practice clinics in the same or a
nearby medical facility. Participants also enrolled at community-based
events, such as Komen Races for the Cure. At each site both cases and
controls were enrolled. All participants gave informed consent and
completed a questionnaire providing information on approximately
50 risk factors including their medical history, family history of cancer,
and lifestyle factors; in addition they provided a buccal cell sample in
commercial mouthwash. The initial model building study set consisted
of 5022 Caucasian females: 1671 breast cancer cases and 3351 age-matched cancer-free controls, and the validation study set consisted of
1193 Caucasian females: 400 breast cancer cases and 793 age-
matched cancer-free controls.
2.2. High incidence Marin study population
This population-based case–control study has previously been de-
scribed [35,36]. Brieﬂy, eligible cases included any female resident of
Marin County diagnosed with primary breast cancer between 1997
and 1999. The 285 cases identiﬁed with breast cancer were matched
by age at diagnosis and ethnicity (non-Hispanic Caucasian) to 286 eligi-
ble controls selected by randomdigit dialing. All enrolled and consented
participants completed a comprehensive questionnaire about lifestyle,
reproductive and clinical risk factors (including personal medical
history and family history of breast cancer). Of note, a prior report of
this study based on the questionnaire data showed no signiﬁcant differ-
ences between the case and control study groups for common breast
cancer risk factors such as those used in BCRAT, including age, age at
menarche, age at ﬁrst live birth, number of ﬁrst-degree relatives with
breast cancer, history and outcome of previous breast biopsies [36].
With the exception of alcohol consumption, additional risk factors in-
cluding use of hormone replacement therapy, prior therapeutic expo-
sure to radiation, as well as residence time in Marin County were
found to be statistically unassociated with breast cancer risk [36]. The
majority of participants completing the Marin questionnaire, including
164 cases and 174 controls, also donated buccal samples which were
initially cryobanked for later DNA analysis. The Investigational Review
Board at University of California, San Francisco approved the informed
consent process, design and protocol for this Marin study.
2.3. DNA isolation and genotyping
Processing of all coded buccal samples for DNA extraction and
genotypingwas performed blinded to case or control study assignment.
Genomic DNA was isolated by a Gentra PureGene DNA puriﬁcation kit
(Gentra, Minneapolis, MN), and genotyping was performed using
microbead-based allele-speciﬁc primer extension (ASPE) followed by
analysis on the Luminex 100™ (Luminex, Inc. Austin, TX) as previously
described [26,32]. For all assays, at least 5% of the specimenswere geno-
typed in duplicate with a concordance rate of N99%.
2.4. Selection of candidate gene polymorphisms (SNPs)
Coded DNA samples from the model building and validation study
populations were genotyped for 117 common, functional polymor-
phisms from 87 distinct candidate genes (Supplementary Table 1).
These SNPs were selected from thousands of candidates considered
from published papers, reviews and meta-analyses as well as genomic
cancer databases such as Online Mendelian Inheritance in Man
(OMIM) and the Cancer Genome Anatomy Project (CGAP). The candi-
date gene markers used for model building were ultimately narrowed
by applying the following selection criteria: (1) associated with risk of
breast or other cancers in at least one peer-reviewed publication, or
having a plausible physiological role in a major pathway implicated in
breast carcinogenesis; (2) demonstrated or predicted to have functional
physiological consequences, including non-synonymous amino acid
substitutions in protein-coding regions leading to alterations in enzy-
matic activity or regulatory sequence changes (promoter or 3′UTR);
and (3) a minor allele common in major ethnic groups. For Caucasians,
the minor allele frequencies ranged between 0.01 and 0.50, with a me-
dian and mean of 0.30 and 0.28, respectively. These SNP candidates
were in genes encoding hormone receptors, extra-cellular matrix pro-
teins, immune modulators, modulators of oxidative potential, growth
factors and signalingmolecules, aswell as proteins involved in synthesis
andmetabolism of steroid hormones and relatedmolecules, DNA repair
and metabolism, cell cycle control and apoptosis.
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Demographic variables and allelic frequencies were very similar in
different geographic areas (Supplemental Table 1) [32]. Therefore, all
sample sourceswere combined to derive themodel building and valida-
tion study sets. The combined model building and validation datasets
contained 2071 Caucasian cases and 4144 controls between the ages
of 30 and 69, with age for cases being their age at diagnosis and age
for controls being their age at the time of study enrollment. The com-
bined dataset was randomly divided, with 80% for model building and
the remaining 20% for validation. Clinical risk factors for each set of par-
ticipants were similar (Supplementary Table 2); both model building
and validation DNA samples were kept entirely separate. The genotype
frequencies in the general population at steady state are expected to be
inHardyWeinberg Equilibrium(HWE). Before its use inmodel building,
the goodness-of-ﬁt χ2-test was used to conﬁrm HWE [37]. Ten of the
117 candidate SNPs did not conform to HWE expectations (p ≤ 0.05)
and were excluded from further analyses. The primary analytical goal
was to systematically evaluate genotypic and clinical/lifestyle factor as-
sociations with case–control status using multivariate logistic regres-
sion (MLR) [38]. Our model building strategy took into account the
fact that breast cancer is a complex disease where the effect of a speciﬁc
SNP could vary with age [32,33]. Thus, themodeling analyses evaluated
terms in both age-invariant and age-interactive manners for their con-
tribution to risk estimation, and considered effects of SNPs alone,
SNP–age interactions, and SNP–SNP interactions. To focus model build-
ing on the SNPsmost likely to contribute in a multivariate setting while
simultaneously reducing the dimensionality of the problem [39], we
employed a feature selection strategy to reduce the number of eligible
terms [40]. First of all, we chose the top 25% of SNPs [41,42] based on
a univariate χ2 p-value. Following feature selection, the reduced dataset
wasmodeled with a forward stepwise selection method with the selec-
tion p-value of 0.1 and the exit p-value of 0.05. To avoid reliance on as-
ymptotic theories for inference, we utilized a bootstrap method for
computing standard errors. Each step in the process was bootstrapped
5000 times [43]. The maximum number of steps allowed was 100.
This analysis was initially performed on the entire model building
dataset to identify informative terms for ages 30 through 69. Published
analyses of several candidate SNPs had demonstrated both “pre-” and
“post-” menopause speciﬁc associations when stratiﬁed at age 50 or
byﬁrst-degree relative status [32,44–51]. To capture these complexities,
age strata (30–49 and 49–69) were also analyzed stratiﬁed on presence
or absence of at least oneﬁrst-degree relativewith breast cancer. To keep
our models parsimonious, informative terms identiﬁed for ages 30–69
were not included as candidate terms in subsequent analyses. Additional
informative terms were identiﬁed for the 30–49 age stratum both with
and without family history of breast cancer. However, analyses of the
age 50–69 groupdid not identify additional informative terms. The infor-
mative terms identiﬁed overall (30–69) and within each strata of 30–
49 year olds (by family history) were combined and maximum likeli-
hood estimates were used to produce a single integrated PFRM which
was used to compute an individual relative risk. Using SEERbreast cancer
incidence and competing mortality rates [52] by the described methods
[7,53], the PFRM was used to estimate the probability of developing
breast cancer from the individuals' current age over the next 5 years
and to estimate lifetime risk up to age 90.
2.6. Performance comparison and calibration of optimized PFRM relative to
BCRAT
The performance of the optimized PFRMwas examined in compari-
son to the BCRAT alone. Model performance was evaluated for women
≥35 years of age in the model building and validation populations.
The OR was used to compare the proportion of cases and controls at
various risk thresholds output by each model (≥1.5, 1.67, 2.0, 2.5, etc.
for 5-year risk and ≥12, 13, 14, etc. for lifetime risk). The numbers ofcases and controls were determined at these risk thresholds, and ORs
were calculated at each risk increment to provide a measure of the
strength of association of an elevated risk score with breast cancer
[54]. The OR was calculated individually for both the PFRM and the
BCRAT and plotted. Additionally, positive likelihood ratios (PLRs) were
calculated as the proportion of cases at a given risk threshold divided
by the proportion of disease-free controls at that threshold [55]. The
fold improvement for the PFRM compared to the BCRAT was calculated
by dividing their ORs and PLRs, and statistical signiﬁcance was assessed
using the χ2-test. Area under the receiver operator curve (AUC) analyses
were performed as previously described [56]. Model calibration was
examined as previously described [15]. The average estimated risk at
5-year intervals was determined for controls ≥35 years in the model
building (3176women) and validation (761women) sets for the age in-
tervals b45, 46–55, 56–65, and N65 years. The calculated average risks
were compared to previously published average risks determined for
the same age intervals for 1744 Caucasian control women for the
BCRAT (Gail model 2) and a new version of the BCRAT that included
breast density and weight [15].
3. Results
3.1. Description of the optimized PFRM
Multivariate logisticmodel building based on the population of 5022
Caucasian women (1671 breast cancer cases and 3351 cancer-free con-
trols) resulted in an optimized PFRM containing 22 SNPs (from 19 dis-
tinct genes), age at ﬁrst live birth, number of ﬁrst degree relatives
with breast cancer, and previous biopsy number/outcome. Table 1
shows a detailed description of the genes, the SNPs and their major
functional pathway. The majority of the SNPs are in genes involved in
steroid hormone metabolism or DNA repair. Fig. 1 illustrates how the
multiple gene polymorphisms and clinical risk factors are utilized in
the PFRM. The ellipses are used to illustrate the role of the terms in
the model with terms utilized individually in the left ellipse and those
interacting with age in the right ellipse. The SNP terms in the overlap-
ping region of the two ellipses are weighted both individually (Panel
A, for all women ages 30–69) as well as by interaction with a speciﬁc
age stratum (30–49 years) in the absence (Panel B) or presence (Panel
C) of having an affected ﬁrst degree family relative.
3.2. PFRM performance in the model building and validation study
populations
PFRM performance was examined in comparison to the BCRAT
which, as discussed above, is currently the primary risk evaluation
tool applicable to most women. Fig. 2 shows graphs of the ORs deter-
mined at increasing risk threshold levels for either 5-year or lifetime ab-
solute risk outputs from the PFRM (solid line), compared to BCRAT
(dashed line) and to the random assignment of cases and controls
(solid line). Upper panels show the results for the model building sam-
ple set while the lower panels show the results for the ﬁrst independent
validation set. These graphs clearly illustrate the improved performance
of the PFRM compared to the BCRAT over a broad range of clinically rel-
evant risk ranges. For the PFRM, the OR increases as the risk level out-
puts by the model increase. In contrast, for BCRAT little or no increase
in the OR is found as the risk level outputs by the model increase. The
5-year and lifetime performance characteristics for the PFRM compared
to BCRAT are similar for both the model building and validation sample
sets. Similar relationships between OR and absolute risk outputs were
also observed when considering either 10-year or 15-year time frames
(data not shown). These PFRM performance characteristics are what
would be expected of an improved prediction model, while the nearly
horizontal lines for the BCRAT lie just above what would be observed
for a model that randomly assigns risk (i.e. as many cases as controls
have elevated risk).
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the BCRAT can also be expressed in terms of fold improvement by calcu-
lating the ratio of the PFRM-OR/BCRAT-OR. Table 2 shows these data for
selected risk thresholds for 5-year and lifetime risks in the model build-
ing sample set. For a 5-year risk threshold of ≥1.67% (about the mini-
mum risk for a normal 65 year old Caucasian woman), the PFRM
exhibits a 1.3-fold improvement that is statistically signiﬁcant (p =
0.002). Fold-improvements in 5-year risk estimates for the PFRM over
the BCRAT of 1.4, 1.9 and 2.7 are seen at risk thresholds of ≥2.0, 3.0,
and 4.0%, respectively, that are all statistically signiﬁcant (p = 0.002,
p b 0.0001, and p b 0.0001). Likewise, at least comparable fold improve-
ments are seen in PFRM over BCRAT lifetime risk estimates between 2.6
and 2.8 at risk threshold of≥20 and 25%, respectively, and these are also
highly signiﬁcant (p b 0.0001). The validation set is a smaller sample
and asmight be expected there is some variability in theOR values com-
pared to the larger model building set (Fig. 2, lower vs. upper panels).
Here for the 5-year risks, we observe increased fold improvements of
1.2, 1.2, 1.2, 1.6 and 2.1 at risk thresholds of ≥2.0, 2.5, 3.0 and 3.5%, re-
spectively; these fold improvements trend toward statistical signiﬁ-
cance at 3.0% risk (p = 0.07) and reach signiﬁcance at the 3.5% risk
threshold (p = 0.037). In this validation set and at the ≥20% threshold
for lifetime risk, a 2.0-fold improvement that is statistically signiﬁcant
(p= 0.036) is observed. Thus, despite themuch smaller size of the val-
idation sample set, results similar to those from the model building set
support the overall conclusion that 5-year and lifetime risk estimations
for the PFRM are signiﬁcantly improved over the BCRAT.
The application of receiver operating characteristic (ROC) curve
areas (AUC) to probability-based risk models such as the PFRM and
BCRAT has been controversial but persists as a method of evaluation
[57]. In our analyses we have found that the new PFRM consistently ex-
hibits improved AUCs compared to the BCRAT. Because of the age strat-
iﬁcation used in model building, we performed AUC analysis of 5-year
risk outputs for women that fall into 5-year age intervals. The largest
improvement in the PFRM compared to BCRAT was in women of 35–
39 years of age where the AUC of the PFRM was 0.69 compared to
0.58 for the BCRAT, a difference of 0.11 with a standard error of 0.02, a
statistically signiﬁcant increase (two-sided p= 0.0002). Improvements
in AUC ranging from0.06 to 0.14 (p=0.02 to 0.0003)were observed for
all but one 5-year age group (age 50–54), where the difference of 0.05
did not reach statistical signiﬁcance. The average improvement in
AUCs for the PFRM compared to BCRAT is similar in the age groups
35–49 (0.08) and 50–69 (0.09).Table 1
Polyfactorial risk model— genes, SNPs and function.
Gene Gene name SNP ID — r
ACACA Acetyl coenzyme A carboxylase alpha rs3491526
N/A
rs2252757
COMT Catechol-O-methyltransferase rs4680
CYP11B2 Cytochrome P450, subfamily XIB, polypeptide 2 rs1799998
CYP19 Cytochrome P450, family 19, subfamily A, polypeptide 1 rs10046
CYP1A1 Cytochrome P450, subfamily IA, polypeptide 1 rs4646903
CYP1B1 Cytochrome P450, subfamily IB, polypeptide 1 rs1800440
rs10012
EPHX Epoxide hydrolase rs1051740
ERCC5 Excision repair, complementing defective, in Chinese hamster, 5 rs17655
ESR1 Estrogen receptor 1 rs2077647
IGF2 Insulin-like growth factor II rs2000993
INS Insulin rs3842752
KLK10 Kallikrein-related peptidase 10 rs3745535
MSH6 MutS, E. coli homolog of, 6 rs3136229
RAD51L3 RAD51, S. cerevisiae, homolog of, D rs4796033
SOD2 Superoxide dismutase 2 rs1799725
TNFSF6 Tumor necrosis factor ligand superfamily, member 6 rs763110
VDR Vitamin D receptor rs7975232
XPC Xeroderma pigmentosum, complementation group C rs2228000
XRCC2 X-ray repair, complementing defective, in Chinese hamster, 2 rs32185363.3. PFRM calibration in the model building and validation study
populations
The improved performance of the PFRM is the result of the opti-
mized model generating risk estimates that differ considerably from
those of the BCRAT. Thus, it is important to show that with this change
in risk estimates the improved model remains well calibrated. Table 3
shows a comparison of the average 5-year risks (b45, 46–55, 56–65,
N65 years) calculated for our model building and validation sample
sets. Comparison of these values obtained for average 5-year risks in
our sample sets to published results obtained for the BCRAT (Gail
model 2) and the BCRAT-D/W (Gail model 2 with breast density and
weight) in their control sample set for different age intervals is shown.
These data show that the optimized PFRM is well calibrated, as it pro-
duces average risk estimates very close to the very well calibrated
BCRAT [8,12], as well as to the more recently examined BCRAT-D/W
[15].
3.4. PFRM performance in the high incidence Marin study population
Given that the high incidenceMarin County case–control study pop-
ulation has been previously described and shown to have no signiﬁcant
case association with either traditional risk factors or increase in OR
assessed by BCRAT [35,36], this study population was compared to our
model sample set and PFRM risk scoreswere determined and compared
to BCRATestimates. As shown in Table 4, and consistentwith knownde-
mographic differences between the Marin County and other urban US-
wide SEER populations [35,36], Marin's cases and controls are balanced
with regard to the shown risk characteristics but are signiﬁcantly older
and have later ages at ﬁrst birth than that of the model building cases
and controls. In Table 5, calculated PLRs, based on an elevated lifetime
risk threshold of ≥12%, are shown for both PFRM and BCRAT models,
comparing the Marin and model building sample sets. Consistent with
the previously described OR comparisons between PFRM and BCRAT
in the model building population (Table 2), PLRs also demonstrated a
signiﬁcant improvement for PFRM over BCRAT in this study population
(1.8 fold improvement, p b 0.0001). For the Marin population, in which
BCRAT again shows no predictive value (PLR = 0.9), the PFRM yields a
PLR = 2.2, representing a signiﬁcant 2.4 fold predictive improvement
over BCRAT (p= 0.036). Another measure of improvement in risk esti-
mation is the ability to correctly assign case status at this same thresh-
old level of elevated lifetime risk (≥12%). In the model buildings# Base change SNP location Function
0 T → G Promoter (PIII) Fatty acid synthesis and BRCA1 interaction
T → C Exon 1
T → C IVS17
A → G V158M Steroid hormone metabolism
T → C Promoter, nt-344 Steroid hormone metabolism
T → C 3′UTR Steroid hormone metabolism
T → C 3′UTR Steroid hormone metabolism
A → G N453S Steroid hormone metabolism
C → G R48G
T → C Y113H Xenobiotic metabolism
G → C D1104H DNA repair
T → C S10S Steroid hormone metabolism
G → A IVS, nt3580 Growth factor/hormone
C → T nt1107 Growth factor/hormone
G → T A50S Cell cycle
G → A Promoter, nt-447 DNA repair
G → A R165Q DNA repair
T → C V16A Free radical scavenger
C → T nt-844 Apoptosis
T → G Intron 8 Hormone receptor
C → T A499V DNA repair
G → A R188H DNA repair
Term Age Interaction
Individual Terms
CYP1A1
ACACA (IVS17)
CYP11B2
ESR1
ERCC5
IGF2
NUMREL
ACACA (5’UTR)
VDR
XRCC2
AGEFLB
NBIOP
MSH6
A
Term Age Interaction
Individual Terms
CYP1B1 (N453S)
EPHX
TNFSF6
XPC
COMT
CYP19
INS
C
Term Age Interaction
Individual Terms
ACACA (PIII)
PARITY
RAD51L3 CYP1B1 (R48G)
KLK10
B
SOD2
Fig. 1. Illustration of the polyfactorial risk model. In each panel, the left ellipse shows the
individual terms in the model and the right ellipse shows the terms interacting with age.
The overlapping region in the middle shows terms included both individually and
interacting with age. Panel A is for all ages, Panel B is for ages 30–49without a ﬁrst degree
relative and Panel C is 30–49 with a ﬁrst degree relative.
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over BCRAT; in the Marin study sample set, PFRM showed a 51% im-
provement in identifying case status over BCRAT, again pointing to the
improved predictive power of PFRM in populations with increased
breast cancer risk.
3.5. A CYP11B2 variant within PFRM and Marin breast cancer risk
Given that the optimized PFRM incorporates 22 functional SNP can-
didates with potential cancer relevance, one question arising from
the Marin study given the improved performance of PFRM over BCRAT
is the relative predictive value of those 22 functional SNPs compared
to 7 other well characterized but non-functional GWAS SNPs(rs2981582/FGFR2, rs3817198/LSP1, rs889312/MAP3K, rs4415084/
MRPS30, rs13281615/POU5F1P1, rs13387042/TNP, rs3803662/TOX3),
previously associated with breast cancer risk and also genotyped in
the same Marin study. For purposes of comparison with PFRM, a com-
posite GWAS-7/BCRAT risk scorewas determined bymultiplying the es-
timated risk for each genotype in the Marin population using
established ORs and determined allele frequencies. The resulting PLR
fold improvement for the GWAS-7/BCRAT lifetime risk estimate over
the basic BCRAT risk estimate in the Marin study set was found to be
1.4 (1.1, 5.3 CI), indicating that in this high risk breast cancer population
the use of 22 functional SNPs in PFRM with its 2.4 fold improvement
over BCRAT offers measureable predictive improvement (2.4/1.4 =
1.7 fold) over the inclusion of 7 GWAS SNPs combined with BCRAT.
This observation also led to a search among the22 SNPs in PFRM for spe-
ciﬁc functional gene variants most enriched in the Marin population
having elevated (≥12%) PFRM risk. Despite the fact that increased
Marin breast cancer risk has been shown to be due to an excess annual
incidence of estrogen receptor (ER)-positive breast cancers [58], the
two PFRM SNPs most closely associated with ER or its metabolism
(rs2077647/ESR1, rs4680/COMT) suggested no genotype enrichment
linked to elevated PFRM risk in Marin. However, three other PFRM
SNPs functionally associatedwith steroid hormonemetabolism showed
some enrichment (in order of magnitude): rs1799998/CYP11B2,
rs7975232/VDR, and rs1800440/CYP1B1. A pilot study suggested possi-
ble risk association with the vitamin D receptor polymorphism
(rs7975232/VDR) in this same Marin population [59], but a recent
meta-analysis has shown no signiﬁcant risk associationwith this specif-
ic VDR SNP in other breast cancer populations [60]. Attention therefore
focused on the PFRM SNPwith the greatest genotype enrichment in the
higher risk Marin population, the aldosterone synthase gene variant
CYP11B2 (rs1799998), known for its functional and epidemiological
link to essential hypertension [61,62] and previously associated
with breast cancer risk in an age-speciﬁc manner [32]. As summa-
rized in Table 6, while the C/C genotype of this CYP11B2 promoter
variant (-344T/C) is found in 20% of the overall Marin study popula-
tion, it occurs in 48% of those with elevated PFRM risk, representing a
signiﬁcant 2.4 fold frequency enrichment associated with increased
breast cancer risk in Marin (p b 0.0001).
4. Discussion
Providing personalized risk assessment for women undergoing
breast cancer screening is an increasingly important concern among
all health care providers and consumers. If women with a higher life-
time risk of developing breast cancer can be accurately identiﬁed rela-
tively early in life, they could be offered more intensive surveillance
(e.g. screening by magnetic resonance imaging) as well as prevention
measures, both in a more clinically and cost effective manner. As one
of the stronger known clinical risk factors, ﬁrst degree family history
of breast cancer is identiﬁed in only ~10% of all breast cancer cases,
and while genetic risk assessment by screening for BRCA1 and BRCA2
mutations can be lifesaving for women with the greatest lifelong sus-
ceptibility to developing familial breast and ovarian cancers, the fre-
quency of these highly penetrant germline mutations in the general
population is only 0.2% [58,59]. In contrast, all women carry common
genetic polymorphisms (SNPs) with variably low penetrant risk con-
nections to sporadic breast cancer development. The BCRAT, which em-
ploys only clinical risk factors but has long been used to identify
populations that can beneﬁt from prevention protocols [7,8], has also
been criticized for lacking the discriminatory accuracy needed for
more individualized risk assessment and counseling [12,13]. Unfortu-
nately, efforts to improve the predictive value of BCRAT by incorporat-
ing some of the strongest risk-associated GWAS SNPs (e.g. GWAS-7/
BCRAT) have achieved only limited success [27–31].
In the present study, we describe the building, performance and cal-
ibration of an optimized PFRM that incorporates the same ﬁve clinical
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Fig. 2. Odds ratio of breast cancer at increasing model 5-year and lifetime risk scores. Odd ratios (ORs) were calculated at increasing model absolute risk outputs for both the PFRM and
BCRAT. The relationships between the OR (y-axis) and risk score (x-axis) are shown for both model building and validation sample sets, and for both 5-year and lifetime risk scores, as
indicated. The PFRM is represented by the solid line with circles and the BCRAT is represented by the dotted lines with squares. The solid line at OR = 1 illustrates the line that would
be obtained for a model with random assignment of risk scores. The plots are initiated at the mean control population risk obtained from the PFRM.
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known functional relevance. This optimized PFRM consistently
outperformed the BCRAT in all case–control study sets evaluated, in-
cluding the model building and two other geographically independent
validation populations, totaling 6553 Caucasian women (2236 cases,
4317 controls). Across all three populations, using either ORs or PLRs
to estimate risk prediction performance over either 5-year or lifetime
risk intervals, the PFRM proved to have at least two fold better predic-
tive performance than BCRAT. At the high lifetime risk threshold of
≥20%, fold improvements in OR for PFRM over BCRAT were 2.6 (p b
0.0001) and 2.0 (p = 0.036) for the model building and validation
sets, respectively, and at the lower lifetime risk threshold of ≥12%
(1.5× the SEER average risk over ages 30–69), fold improvements in
PLR for PFRM over BCRAT were 1.8 (p b 0.0001) and 2.4 (p = 0.036)
for the model building and Marin populations, respectively. For the
high incidence Marin population in particular, at the 12% risk threshold
the BCRAT showed virtually no predictive ability (0.9 PLR), unlike theTable 2
Fold improvement in ORs at selected risk thresholds.
Risk threshold OR (95% CI)a Fold improvement
(95% CI)
p-Value
PFRM BCRAT
5-Year (%)
1.67 1.6 (1.4, 1.9) 1.2 (1.1, 1.3) 1.3 (1.1, 1.4) 0.002
≥2.0 1.8 (1.6, 2.1) 1.3 (1.1, 1.5) 1.4 (1.1, 1.6) 0.002
≥3.0 2.8 (2.2, 3.5) 1.4 (1.2, 1.7) 1.9 (1.4, 2.5) b0.0001
≥4.0 4.3 (3.0, 6.0) 1.5 (1.2, 2.0) 2.7 (1.8, 4.1) b0.0001
Lifetime (%)
≥20 4.3 (3.0, 6.0) 1.7 (1.4, 2.0) 2.6 (1.8, 3.8) b0.0001
≥25 5.6 (3.4, 9.1) 2.0 (1.7, 2.6) 2.8 (1.7, 4.7) b0.0001
a OR = odds ratio and CI = conﬁdence interval.PFRM (2.2 PLR) which proved nearly 2-fold better at assigning case
status among theMarin case–control study samples. Although the stan-
dard BCRAT, as employed in all these population set comparisons with
PFRM, does not incorporate SNPs into its risk estimation, in two prelim-
inary studies we have reported that the PFRM signiﬁcantly outperforms
risk scores obtained using either a core group of 7 GWAS SNPs alone or
in combination with BCRAT [63,64]; those latter results obtained using
the Marin study population are now presented here.
The full panel of 117 functional SNPs originally included in the PFRM
model building was selected based on their biological and physiological
plausibility in contributing to the development of breast and related
cancers. Based on the importance of estrogens in inﬂuencing breast can-
cer risk and development, perhaps it is not surprising that the majority
of the 22 SNPs ending up in the optimized model were genes related to
steroid hormonemetabolism and DNA repair, with 7 of the SNPs occur-
ring in genes involved in steroid hormone synthesis, signaling ormetab-
olism and 5 within genes related to DNA repair. Curiously, in the Marin
population at highest risk for developing ER-positive breast cancer [58],
neither ESR1 (encoding ERα) nor COMT (encoding the catechol-O-Table 3
Polyfactorial risk model calibration.
Average predicted 5-year risk intervals (%)
Age ≤ 45 Age 46–55 Age 56–65 Age N 65
Model building PFRM 0.7 1.4 2.0 2.4
BCRAT 0.8 1.7 2.4 2.7
Validation PFRM 0.7 1.4 2.1 2.3
BCRAT 0.8 1.5 2.4 2.4
Published
BCRAT [15]
BCRAT 0.7 1.5 2.1 1.9
BCRAT-D/W 0.8 1.5 2.2 1.9
Table 4
Comparison of the Marin and model building case–control populations.
Number of ﬁrst
degree relatives
Marin County Model building
Cases Controls Cases Controls
Mean agea (SD) 53.6 (8.17) 54.2 (7.88) 49.7 (9.2) 49.7 (9.3)
Mean age at menarche (SD) 12.7 (1.4) 12.5 (1.4) 12.3 (2.5) 12.5 (2.3)
Mean age at ﬁrst live birth (SD) 27.5 (5.8) 27.9 (6.1) 24.2 (5.1) 24.0 (5.2)
First degree 0 138 (82) 136 (77) 1308 (78) 2531 (75)
Relatives 1 29 (17) 37 (21) 332 (20) 733 (22)
N (%) ≥2 2 (1) 4 (2) 31 (2) 87 (3)
a Age at diagnosis cases and age enrollment controls; SD = standard deviation.
100 E.R. Jupe et al. / BBA Clinical 2 (2014) 94–102methyltransferase that metabolizes estrogen) demonstrated any signif-
icant genotype frequency enrichment associated with increased PFRM
risk, although it is important to note that all of the weakly penetrant
SNPs in the PFRM contributed in assigning individual risk within the
Marin study set that proved collectively more predictive than either
the BCRAT or clinical risk factors alone. To be singled out, however, for
its contribution to increased PFRM performance in the Marin popula-
tion is one of the steroid hormone metabolizing SNPs, a promoter vari-
ant (-344T/C) of the cytochrome P450 aldosterone synthase gene
CYP11B2, whose C/C genotypewas previously associatedwith increased
breast cancer risk among older age females (55–69 years) [32], but
whose same inherited genotype has gained considerable attention
among vascular researchers for its strong meta-analysis association
with reduced risk of developing essential hypertension in Caucasians
[61,62]. Signiﬁcantly, the CYP11B2 C/C genotype observed in 20% of
the overall Marin study population (consistent with its occurrence in
other Caucasian populations) was found in 48% of those with elevated
PFRM risk in Marin (p b 0.0001).
What connection might a functional gene variant associated with
mechanistic regulation of blood pressure via aldosterone synthesis
also have in determiningbreast cancer risk? As it turns out, a very recent
and independent study of breast cancer risk inMarin County, conducted
by the Marin Women's Study, has uncovered a novel association be-
tween the protective effect of pregnancy-induced hypertension (PIH)
and later life breast density and breast cancer risk, modiﬁed strongly
by two speciﬁc SNPs (rs3025039/VEGF, rs2016347/IGFR1) [65]. WhileTable 5
Fold improvement in PLRs at elevated risk threshold.a
Sample set PLR (95% CI) Fold improvement
(95% CI)
p-Value
PFRM BCRAT
Marin County 2.2 (1.1, 4.3) 0.9 (0.6, 1.3) 2.4 (1.1, 5.65) 0.036
Model building 2.1 (1.8, 2.5) 1.2 (1.1, 1.3) 1.8 (1.4, 2.2) b0.0001
a ≥12%, PLR = positive likelihood ratio, and CI = conﬁdence interval.
Table 6
CYP11B2 genotypes and frequencies in Marin case–control population.
CYP11B2 rs1799998 C/C C/T T/T n
n (%) n (%) n (%)
PFRM ≥ 12%a 16 (48)⁎ 14 (42) 3 (9) 33
Overall study 68 (20)⁎⁎ 167 (49) 103 (30) 338
Cases 28 (17) 89 (54) 47 (29) 164
Controls 40 (23) 78 (45) 56 (32) 174
Elevated risk/all 48%/
20% = 2.4⁎⁎⁎
42%/
49% = 0.86
9%/
30% = 0.30
a 1.5× the SEER average risk for age range 30–69.
⁎ Mean age (SD) = 56.6 (7.4), 31% ≥ 60.
⁎⁎ Mean age (SD) = 53.9 (8.3), 29% ≥ 60.
⁎⁎⁎ With a one sample t-test of proportions, p b 0.0001, CI = 0.34–0.69.neither PIH nor those two VEGF and IGFR1 SNPs were assessed in the
Marin case–control study set evaluated here, it is of mechanistic rele-
vance that the same CYP11B2 promoter SNP linked here toMarin breast
cancer risk has previously been implicated (along with VEGF and inap-
propriate aldosterone production) in the genetic and pathophysiologic
basis for the hypertensive pregnancy disorder known as preeclampsia
[66–68]. Based on our PFRM ﬁndings in the Marin population, future
studies should now explore the age- and ethnicity-dependent mecha-
nism potentially connecting inherited aldosterone-altering CYP11B2
variants with premenopausal predisposition to PIH or preeclampsia,
and postmenopausal breast cancer risk.
A major strength of the current study is the presentation of a new
PFRM with signiﬁcantly improved model performance over BCRAT, as
validated in two independent study populations while maintaining
model calibration. Another strength is inclusion of the Marin County
case–control validation study set, with its age and ethnicity matching
drawn from a known high incidence breast cancer population.
However, a signiﬁcant limitation of this latter validation study is that re-
cruitment was retrospective and it represents a relatively small study
sample. Therefore, observations drawn from this validation study,
including the ﬁnding of higher breast cancer risk linked to a CYP11B2 al-
dosterone synthase SNP, should be considered hypothesis generating
and must be tested in another independent, larger, age- and ethnicity-
matched population study. Future evaluation of the PFRM in a large,
longitudinally followed study cohort is also needed to further validate
its general applicability, conﬁrm its calibration, and prospectively test
its individualized prediction estimates. Further validation of its im-
proved level of individualized risk prediction could immediately impact
clinical practice by more accurately identifying women most likely to
beneﬁt frommore frequent clinical surveillance, more sensitive screen-
ing methods, and/or more aggressive prevention intervention.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2014.11.001.Acknowledgements
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